Shuttle Pharmaceuticals Holdings said it received a notification from the NASDAQ Exchange indicating that its common stock may be delisted unless the company submits a compliance plan by October 27, 2026.
The exchange cited a violation of Listing Rule 5250(c)(1), which requires timely filing of quarterly reports. Shuttle failed to file its Form 10-Q for the fiscal quarter ended June 30, 2026, within the required timeframe. The company’s stock remains listed and tradable for now, but faces potential delisting if the situation is not resolved.
Shuttle Pharmaceuticals operates a pharmaceutical software platform focused on molecular discovery and early-stage drug development. Its wholly-owned subsidiary, United Dogecoin, provides digital infrastructure for blockchain networks, artificial intelligence, and high-performance computing workloads. The company is based in Gaithersburg, Maryland.
NASDAQ has set a compliance plan deadline of October 27, 2026. If the plan is accepted, Shuttle may receive an extension of up to 180 calendar days from the original Form 10-Q due date, pushing the final deadline to February 22, 2027. Failure to meet these requirements could result in delisting.
Shuttle’s shares closed at $3.54 on August 28, 2026, down 8.76% from the previous session. The decline followed the announcement of the compliance issue.
The company has not indicated whether it plans to appeal the notification or provide additional details on its filing status.
